<?xml version="1.0" encoding="UTF-8"?>
<p id="Par45">The primary endpoint is the 1-year PFS. Progression Free Survival PFS is defined as the time from randomization until the date of the first objective progression or death (whatever its cause in the absence of progression). Stereo-OS protocol will allow a specific focus on skeletal metastases and is thus expected to bring a clear-cut assessment of the added benefit of stereotactic radiotherapy on PFS.</p>
